URGN Stock Summary and Trading Ideas (Urogen Pharma Ltd. - | NASDAQ:URGN)

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Urogen Pharma Ltd. - trades on the NASDAQ stock market under the symbol URGN.

As of September 21, 2026, URGN stock price declined to $43.20 with 451,002 million shares trading.

URGN has a beta of 1.98, meaning it tends to be more sensitive to market movements. URGN has a correlation of 0.16 to the broad based SPY ETF.

URGN has a market cap of $2.10 billion. This is considered a Mid Cap stock.

Last quarter Urogen Pharma Ltd. - reported $72 million in Revenue and -$.28 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.03.

In the last 3 years, URGN traded as high as $50.81 and as low as $3.42.

The top ETF exchange traded funds that URGN belongs to (by Net Assets): IWM, IWO, IBB, VTWO, FESM.

URGN has outperformed the market in the last year with a return of +128.9%, while the SPY ETF gained +18.5%. In the last 3 month period, URGN beat the market returning +28.7%, while SPY returned +3.8%. However, in the most recent 2 weeks URGN has underperformed the stock market by returning -2.0%, while SPY returned +0.7%.

URGN support price is $41.96 and resistance is $44.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that URGN shares will trade within this expected range on the day.